Commitment to Investor

Rhea-AI Summary

Kelyniam Global (OTC:KLYG), a manufacturer of custom cranial and craniofacial implants, has achieved an uplisting to the OTCID market tier on the OTC Markets Group platform. This upgrade reflects the company's commitment to transparency and compliance with financial reporting requirements.

The OTCID status distinguishes KLYG among OTC companies, requiring regular financial reporting and compliance with strict criteria. CFO Terrance Kurtenbach highlighted that this achievement could attract a broader investor base while supporting long-term growth. The company continues to focus on expanding its product portfolio, including PEEK cranial implants with patented fixation and regenerative products.

Positive

• Uplisting to OTCID tier demonstrates enhanced transparency and compliance
• Potential to attract broader investor base through improved market visibility
• Maintains ongoing reporting obligations, fostering greater investor confidence

Negative

• None.

Excellence Kelyniam Global, Inc. Uplists to OTCID Market Tier

CANTON, Conn., Sept. 8, 2025 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and craniofacial implants, today announced that it's share trading platform has been elevated to OTCID status on the OTC Markets Group platform. This designation underscores the Company's commitment to transparency and compliance, providing investors with enhanced access to current financial information and market data.

Terrance Kurtenbach, Chief  Financial Officer of Kelyniam said, "Only a select group of OTC companies qualify for OTCID status, as it demands regular financial reporting and compliance with OTC Markets' criteria—a level of rigor that many OTC-listed entities do not meet. This distinction positions Kelyniam among a more transparent subset of the OTC ecosystem, potentially attracting a broader investor base and supporting long-term growth.

"We are  very excited  to have our shares moved to the elevated OTCID trading platform", This achievement not only validates our operational discipline but also enhances our ability to communicate effectively with the investment community as we continue to innovate in the custom cranial implant space."

"Unlike non-reporting tiers like Pink No Information or Expert Market, OTCID companies must maintain ongoing reporting obligations, including timely disclosures of financial statements and material events, which fosters greater investor confidence and facilitates more efficient trading. We applaud OTC Markets continued efforts to distinguish and elevated registrants with viable business operating models and robust governance and reporting standards in providing investors with reliable information and opportunity"

Kelyniam Global, Inc. remains focused on expanding its product portfolio, including its PEEK cranial implants with patented fixation, and regenerative products that include CustomizedBone© (hydroxy apatite) implants and the Osteopore line of implants.

About Kelyniam Global, Inc. Kelyniam Global, Inc. specializes in the rapid production of custom cranial and craniofacial implants made from PEEK, a biocompatible polymer. The Company collaborates with neurosurgeons worldwide to deliver high-quality, patient-specific implants with a turnaround time of 48 hours. Kelyniam is committed to advancing medical technology and improving patient outcomes through innovation and precision manufacturing. For more information, visit www.kelyniam.com.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Investors are cautioned not to place undue reliance on these forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/commitment-to-investor-302548478.html

SOURCE Kelyniam Global Inc

FAQ

What does Kelyniam Global's uplisting to OTCID mean for investors?

The OTCID uplisting requires KLYG to maintain regular financial reporting and compliance, providing investors with enhanced transparency and access to current financial information.

What are the requirements for Kelyniam (KLYG) to maintain OTCID status?

KLYG must maintain ongoing reporting obligations, including timely disclosures of financial statements and material events, meeting OTC Markets' strict compliance criteria.

What products does Kelyniam Global (KLYG) manufacture?

Kelyniam Global manufactures custom cranial and craniofacial implants, including PEEK cranial implants with patented fixation, CustomizedBone© hydroxy apatite implants, and the Osteopore line of implants.

How does OTCID status differ from other OTC market tiers?

OTCID status requires higher standards of transparency and reporting compared to other tiers like Pink No Information or Expert Market, indicating a more robust governance structure.